Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

COVID prevention drugs fail in hospital worker trial

NCT ID NCT04344379

Prevention Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether hydroxychloroquine or azithromycin could prevent COVID-19 infection in hospital workers who were regularly exposed to the virus. 122 participants took one of the drugs or a placebo for 40 days. The study found no significant difference in infection rates between the groups, meaning these drugs did not prevent COVID-19.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

122 people

The number who actually took part.

Started

Apr 2020

Finished

Jun 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Hospital workers working at AP-HP hospitals over the age of 18 * Hospital workers who have signed consent * No signs of COVID-19 infection * Women who are likely to procreate should have a negative pregnancy test on inclusion day. In addition, they should use at least one effective contraceptive method before starting treatment, during treatment and up to 8 months after the last drug tested during the trial. Sexually active men should also have effective contraception during treatment and for at least 8 months after the last drug tested during the trial. * Affiliated or beneficiary of Social Security Exclusion Criteria: * History of SARS-CoV-2 infection confirmed by PCR or serology is available at inclusion * A history of clinical episode suspecting a PCR-confirmed or unconfirmed COVID-19 infection. * Pregnancy and breastfeeding * Allergy or contraindications to one of the 2 drugs in the study * Known retinopathy * Long congenital QT syndrome (or known in the family) * QTc or 450 ms in men, or 460 ms in women, if Fc 55/mn (except in case of intense sport practice), if ESV on baseline ECG, if QRS - or 120 ms, if AC/FA, if the PR or BAV lengthening * History of severe ischemic heart disease or unbalanced heart failure. * Clinically significant bradycardia known * Known kidney or liver failure * Known G6PD deficit * Subject who received antiviral treatment in the 14 days prior to inclusion * Subject who had treatment with azithromycin or hydroxychloroquine, in the 14 days prior to inclusion * Hypokaliemia (\<= 3.5 mmol/L), Increase in creatinine (\>=120 micromol/Ll, Increase in transaminases at baseline (\>=2N)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-CoV-2 infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARS-CoV-2 infection

Contacts and locations

Locations

  • Hopial Avicenne

    Bobigny, 93000, France

  • Hôpital Broca

    Paris, 75013, France

  • Hôpital Cochin

    Paris, 75014, France

  • Hôpital GHU Paris Saclay

    Le Kremlin-Bicêtre, 92100, France

  • Hôpital La Pitié-Salpétrière

    Paris, 75013, France

  • Hôpital Necker

    Paris, 75015, France

  • Hôpital Saint Antoine

    Paris, 75012, France

  • Hôpital européen Georges Pompidou

    Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.